



# Pharmacy Facts

## MassHealth Pharmacy Program

[www.mass.gov/masshealth/pharmacy](http://www.mass.gov/masshealth/pharmacy)

• Editor: Vic Vangel • Contributors: Paul Jeffrey, Kim Lenz, James Monahan, Nancy Schiff, Vic Vangel •

### MHDL Update

#### 1. Additions

Effective March 6, 2017, the following newly marketed drugs have been added to the MassHealth Drug List.

- Adlyxin (lixisenatide) – **PA**
- Basaglar (insulin glargine 100 units/mL prefilled syringe) – **PA**
- Bromsite (bromfenac 0.075%) – **PA**
- Inflectra (infliximab-dyyb) – **PA**
- Lartruvo (olaratumab) – **PA**
- Royaldee (calcifediol) – **PA**
- Soliqua (insulin glargine/lixisenatide) – **PA**
- Sustol (granisetron extended-release injection) – **PA > 2 units/ 28 days**
- Vemlidy (tenofovir alafenamide) – **PA**
- Xultophy (insulin degludec/liraglutide) – **PA**
- Yosprala (aspirin/omeprazole) – **PA**
- Zinplava (bezlotoxumab) – **PA**

#### 2. Change in Prior Authorization Status

- a. Effective March 6, 2017, the following vitamin D analog agents will require prior authorization.
  - Hectorol (doxercalciferol capsule) – **PA**
  - Zemplar (paricalcitol capsule) – **PA**
- b. Effective March 6, 2017, the following vitamin D analog agents will be restricted to the health care professional who administers the drug. MassHealth will not pay for these drugs to be dispensed through a retail pharmacy.
  - Hectorol (doxercalciferol injection)<sup>^</sup>
  - Zemplar (paricalcitol injection)<sup>^</sup>
- c. Effective March 6, 2017, the following smoking cessation agents will no longer require prior authorization.
  - Nicotrol Inhaler (nicotine inhalation system)
  - Nicotrol NS (nicotine nasal spray)
- d. Effective March 6, 2017, the following smoking cessation agent will no longer require prior authorization for exceeding duration of therapy limits.
  - Chantix (varenicline)
- e. Effective March 6, 2017, the following scabicide agent will require prior authorization.
  - Eurax (crotamiton) – **PA**

#### 3. MassHealth Brand Name Preferred Over Generic Drug List

- a. Effective March 6, 2017, the following anti-acne dermatological agents will be added to the Brand Name Preferred Over Generic Drug List.
  - Differin (adapalene)<sup>BP</sup> – **PA**
  - Retin-A (tretinoin)<sup>BP</sup> – **PA ≥ 22 years**
- b. Effective March 6, 2017, the following inhaled respiratory agents will be added to the Brand Name Preferred Over Generic Drug List.
  - Advair (fluticasone/salmeterol)<sup>BP</sup> – **PA**
  - Proair HFA (albuterol inhaler)<sup>BP</sup>
- c. Effective March 6, 2017, the following lipid lowering agent will be added to the Brand Name Preferred Over Generic Drug List.
  - Vytorin (ezetimibe/simvastatin)<sup>BP</sup> – **PA**
- d. Effective March 6, 2017, the following antidepressant agent will be added to the Brand Name Preferred Over Generic Drug List.
  - Pristiq (desvenlafaxine succinate extended-release)<sup>BP</sup> – **PA**
- e. Effective March 6, 2017, the following Attention-Deficit/Hyperactivity Disorder agent will be added to the Brand Name Preferred Over Generic Drug List.
  - Strattera (atomoxetine)<sup>BP</sup> – **PA < 6 years**

**PA** Prior authorization is required. The prescriber must obtain prior authorization for the drug in order for the pharmacy to receive payment. Note: Prior authorization applies to both the brand-name and the FDA “A”-rated generic equivalent of listed product.

**#** This designates a brand-name drug with FDA “A”-rated generic equivalents. Prior authorization is required for the brand, unless a particular form of that drug (for example, tablet, capsule, or liquid) does not have an FDA “A”-rated generic equivalent.

**BP** Brand Preferred over generic equivalents. In general, MassHealth requires a trial of the preferred drug or clinical rationale for prescribing the non-preferred drug generic equivalent.

**\*** The generic OTC and, if any, generic prescription versions of the drug are payable under MassHealth without prior authorization.

**^** This drug is available through the health care professional who administers the drug. MassHealth does not pay for this drug to be dispensed through a retail pharmacy.

## Cost of Dispensing Survey

Many MassHealth Pharmacy Providers participated in a cost of dispensing survey performed by Myers and Stauffer LC, beginning in September 2016. A summary of that survey has been posted on the MassHealth Pharmacy Web Site.

To view the summary, go to [www.mass.gov/masshealth/pharmacy](http://www.mass.gov/masshealth/pharmacy) and click on the link for MassHealth Cost of Dispensing Survey Report.